{"id":19699,"date":"2023-04-13T20:32:00","date_gmt":"2023-04-13T12:32:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19699"},"modified":"2024-12-24T20:36:35","modified_gmt":"2024-12-24T12:36:35","slug":"diapin-therapeutics-announces-breakthrough-preclinical-results-for-dt-109-in-nash-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19699","title":{"rendered":"Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment"},"content":{"rendered":"\n

US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its novel oral tripeptide compound, DT-109, which has demonstrated the ability to inhibit the progression of non-alcoholic steatohepatitis (NASH) in monkeys. The study, now published in Cell Metabolism, was conducted by Diapin\u2019s founder Dr. Eugene Chen and researchers at Xi\u2019an Jiaotong University and the University of Michigan.<\/p>\n\n\n\n

DT-109’s Impact on Liver Fat and Fibrosis<\/strong>
According to Diapin, the study showed that treatment with DT-109 led to a significant reduction in liver fat, attenuation of fibrosis, and improvement in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), a critical clinical endpoint in NASH clinical trials. These findings position DT-109 as a promising candidate for further development. The compound is now being prepared to enter clinical trials in 2024.<\/p>\n\n\n\n

Mechanism of Action and Broad Potential Applications<\/strong>
DT-109 is a three amino acid peptide that is believed to act on several pathways, including increasing fatty acid oxidation, decreasing free radicals, and reducing inflammation. These effects are achieved by modulation of the intestinal microbiome and regulation of bacterially produced molecules. Beyond its potential in targeting NASH, DT-109 is also viewed as having potential against various lipid-mediated medical conditions.<\/p>\n\n\n\n

Diapin’s Origins and Global Partnership<\/strong>
Diapin was established by Dr. Chen as a spin-out from the University of Michigan. Among the firm\u2019s earliest investors is China-based Beijing SL Pharmaceuticals Ltd, which will be a strategic partner for the global development of DT-109.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,6],"tags":[2932,76],"class_list":["post-19699","post","type-post","status-publish","format-standard","hentry","category-company","category-rd","tag-diapin-therapeutics","tag-nash"],"yoast_head":"\nDiapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its novel oral tripeptide compound, DT-109, which has demonstrated the ability to inhibit the progression of non-alcoholic steatohepatitis (NASH) in monkeys. The study, now published in Cell Metabolism, was conducted by Diapin\u2019s founder Dr. Eugene Chen and researchers at Xi\u2019an Jiaotong University and the University of Michigan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19699\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19699\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T12:32:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-24T12:36:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19699#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19699\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment\",\"datePublished\":\"2023-04-13T12:32:00+00:00\",\"dateModified\":\"2024-12-24T12:36:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19699\"},\"wordCount\":259,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diapin Therapeutics\",\"NASH\"],\"articleSection\":[\"Company\",\"R&D\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19699#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19699\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19699\",\"name\":\"Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-13T12:32:00+00:00\",\"dateModified\":\"2024-12-24T12:36:35+00:00\",\"description\":\"US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its novel oral tripeptide compound, DT-109, which has demonstrated the ability to inhibit the progression of non-alcoholic steatohepatitis (NASH) in monkeys. The study, now published in Cell Metabolism, was conducted by Diapin\u2019s founder Dr. Eugene Chen and researchers at Xi\u2019an Jiaotong University and the University of Michigan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19699#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19699\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19699#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment - Insight, China's Pharmaceutical Industry","description":"US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its novel oral tripeptide compound, DT-109, which has demonstrated the ability to inhibit the progression of non-alcoholic steatohepatitis (NASH) in monkeys. The study, now published in Cell Metabolism, was conducted by Diapin\u2019s founder Dr. Eugene Chen and researchers at Xi\u2019an Jiaotong University and the University of Michigan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19699","og_locale":"en_US","og_type":"article","og_title":"Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19699","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-13T12:32:00+00:00","article_modified_time":"2024-12-24T12:36:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19699#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19699"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment","datePublished":"2023-04-13T12:32:00+00:00","dateModified":"2024-12-24T12:36:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19699"},"wordCount":259,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diapin Therapeutics","NASH"],"articleSection":["Company","R&D"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19699#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19699","url":"https:\/\/flcube.com\/?p=19699","name":"Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-13T12:32:00+00:00","dateModified":"2024-12-24T12:36:35+00:00","description":"US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its novel oral tripeptide compound, DT-109, which has demonstrated the ability to inhibit the progression of non-alcoholic steatohepatitis (NASH) in monkeys. The study, now published in Cell Metabolism, was conducted by Diapin\u2019s founder Dr. Eugene Chen and researchers at Xi\u2019an Jiaotong University and the University of Michigan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19699#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19699"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19699#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19699"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19699\/revisions"}],"predecessor-version":[{"id":19701,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19699\/revisions\/19701"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}